Article Sidebar
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Comparative bioavailability study of a new quinine suppository and oral quinine in healthy volunteers
Abstract
Purpose: There is the need for alternative and more convenient route of quinine (QN) administration in complicated and severe malaria. The purpose of this study is to compare the bioavailability (BA) of a new quinine suppository made from theobroma oil to that of an existing tablet formulation in healthy volunteers.
Methods: Six healthy volunteers were administered with 300 mg of QN sulphate as suppository and tablet in a crossover manner. QN concentrations in both plasma and urine at predetermined time points were determined spectrofluorimetrically.
Results: Absorption was slower, more variable and lower with the suppository than with the tablet. The time of maximum concentration (Tmax), maximum concentration (Cmax), area under the curve (AUC) and cumulative urinary excretion (Du¥) for the two formulations were also significantly different, with no changes in elimination half-life (t1/2). The respective Cmax and AUC values were 4 to 5 times higher with the tablet (2.32 ± 0.22 mg/ml, 36.31 ± 10.06 mg.h/ml) than with the suppository (0.52 ± 0.37 mg/ml, 7.69 ± 5.79 mg.h/ml). The Du¥ were 9.17 ± 1.11 mg and 2.56 ± 0.55 mg for the tablet and suppository respectively. The relative BA of the suppository was 21.24 ± 16.00 % (95 % C. I., 8.44 – 34.04%) from plasma levels and 26.14 ± 7.80 % (95 C.I., 19.90 – 32.38 %) from urine excretion.
Conclusion: Absorption of this new QN suppository is poor; therefore it may not be therapeutically expedient to substitute it for the tablet form at the same dose. Improving the suppository formulation or increasing the dose in order to increase its BA may be necessary.
Keywords: Quinine, suppository, bioavailability.
> Tropical Journal of Pharmaceutical Research Vol. 3 (1) 2004: pp. 291-297
